Prolactin (PRL): Pituitary Lactotroph Hormone Regulating Lactation, Immune Function, and Reproductive Axis via PRLR/JAK2/STAT5 Signaling in Research

# Prolactin (PRL): Pituitary Lactotroph Hormone Regulating Lactation, Immune Function, and Reproductive Axis via PRLR/JAK2/STAT5 Signaling in Research

Introduction

Prolactin (PRL) is one of the most structurally and functionally versatile hormones in vertebrate biology. Originally characterized solely for its role in milk production and secretion (lactogenesis), subsequent research revealed prolactin to be a pleiotropic cytokine-like hormone with over 300 documented biological activities spanning reproduction, immune regulation, metabolism, angiogenesis, osmoregulation, and neurogenesis.

Produced predominantly by lactotroph cells of the anterior pituitary gland, prolactin is unique among pituitary hormones in being under tonic inhibitory control by dopamine from the hypothalamus, rather than the positive drive that characterizes most hypothalamic-pituitary axes. This means that disruption of dopaminergic signaling — by any cause — results in hyperprolactinemia, making prolactin biology clinically central to understanding medication-induced hormone dysregulation.

The most common cause of hyperprolactinemia is iatrogenic — antipsychotic medications (first and second generation), antiemetics (metoclopramide, domperidone), and other dopamine antagonists all elevate prolactin by blocking D2 receptors on lactotrophs. Hyperprolactinemia causes hypogonadotropic hypogonadism (suppressed GnRH → LH/FSH → testosterone/estrogen) with galactorrhea, amenorrhea, oligospermia, and infertility — correctable by treating the underlying cause or with dopamine agonists.

For researchers, prolactin is a valuable model for studying cytokine signaling (PRLR shares structural and signaling features with hematopoietic cytokine receptors), immune-endocrine crosstalk, and the neuroendocrinology of reproduction and lactation.

Discovery and Characterization

Strieker and Grueter (1928) first demonstrated that anterior pituitary extracts could induce lactation in rabbits — the first evidence of a lactogenic factor distinct from other pituitary hormones.

Riddle, Bates, and Dykshorn (1933) isolated and named "prolactin" after demonstrating it stimulated crop milk production in pigeons — an assay that remained a key bioassay for decades. The pigeon crop sac assay was the principal bioassay for prolactin until immunoassays became available in the 1970s.

Li et al. (1970) completed the primary amino acid sequence of ovine prolactin, revealing its structural relatedness to growth hormone (GH) — the two hormones are thought to share a common ancestral gene.

Human prolactin (human PRL) proved difficult to characterize separately from human GH due to structural overlap, but was definitively isolated and sequenced by the early 1970s. The human prolactin receptor (PRLR) was cloned in 1988 by Boutin et al. (Cell,), revealing membership in the class 1 cytokine receptor superfamily.

Gene Structure and Protein Biochemistry

The PRL gene (chromosome 6p22.3-p21.3) spans ~10 kb with 5 exons. The pituitary-specific promoter drives expression from exon 1b; an alternative "generic" promoter (in extrapituitary sites) drives expression from exon 1a. This explains the distinct regulation of pituitary vs. non-pituitary prolactin.

Mature human prolactin:

• •199 amino acids (after signal peptide cleavage from the 227-aa precursor)
• •Molecular weight: ~23 kDa
• •Globular, 4-helix bundle structure (helices A, B, C, D) — shared with GH, EPO, and other hematopoietic cytokines
• •3 disulfide bonds: Cys58-Cys174 (the long loop), Cys191-Cys199 (short C-terminal loop), and an additional internal one — highly conserved
• •N-glycosylation at Asn31 (and potentially Asn37) contributes to the heterogeneity of circulating prolactin forms

Prolactin Molecular Heterogeneity

Circulating prolactin exists as multiple molecular forms with different sizes and bioactivities:

1. Little prolactin (23 kDa): monomeric; predominant form; fully biologically active

2. Big prolactin (50 kDa): dimeric; partially active; accounts for ~10-20% of circulating PRL

3. Big-big prolactin (macroprolactin, ~150-170 kDa): usually prolactin-IgG complexes; immunoreactive in standard assays but biologically inert; causes macroprolactinemia — a common cause of "laboratory hyperprolactinemia" without clinical symptoms (because macroprolactin cannot cross capillary basement membranes to reach target cells)

4. Cleaved prolactin (16 kDa): cathepsin D cleaves 23 kDa PRL at the long loop → 16 kDa N-terminal fragment; has anti-angiogenic activity (inhibits endothelial cell proliferation) — biologically opposite to the full-length pro-angiogenic PRL

Clinical relevance: When evaluating hyperprolactinemia, macroprolactin should be excluded by polyethylene glycol (PEG) precipitation. If >60% of immunoreactivity precipitates with PEG, macroprolactinemia is likely and treatment may not be necessary despite high measured PRL.

Hypothalamic-Pituitary Regulation: Dopamine Dominance

Tonic Dopaminergic Inhibition

Unlike all other anterior pituitary hormones, prolactin is under dominant tonic inhibition by hypothalamic dopamine:

1. Hypothalamic tuberoinfundibular dopaminergic (TIDA) neurons release dopamine into the portal vessels of the median eminence

2. Dopamine reaches lactotrophs and activates D2 receptors (DRD2)

3. D2R → Gi → reduced cAMP → reduced PKA → reduced CREB → suppressed PRL gene transcription + increased PRL secretion inhibition

4. Any interruption of dopamine delivery → lactotroph "escape" → hyperprolactinemia

This is why:

• •Dopamine antagonists (antipsychotics, metoclopramide) reliably increase prolactin
• •Stalk compression from non-secreting pituitary tumors disrupts portal blood flow → hyperprolactinemia without intrinsic lactotroph dysfunction
• •Dopamine agonists (cabergoline, bromocriptine) are used to treat hyperprolactinemia by replacing the lost dopaminergic signal

Prolactin-Releasing Factors

Although dopamine dominates, several factors stimulate prolactin release:

• •TRH (thyrotropin-releasing hormone): second most important PRL secretagogue; explains why hypothyroidism (with elevated TRH) causes hyperprolactinemia
• •Vasoactive intestinal peptide (VIP): potent PRL stimulator; locally produced in pituitary
• •Serotonin: 5-HT2A/2C → PRL release; may explain antidepressant-associated PRL elevation
• •Oxytocin: released with suckling → synergizes with nipple stimulation to drive PRL
• •Estrogen: increases lactotroph sensitivity and PRL gene expression (explains PRL elevation in pregnancy)
• •Prolactin-releasing peptide (PrRP/PRRP): a 20-31 aa peptide acting at GPR10; modest PRL-releasing activity but likely involved primarily in hypothalamic energy sensing and HPA regulation

Suckling-Driven PRL Surges

Breastfeeding produces remarkable neuroendocrine reflex:

1. Infant suckling → sensory afferents → spinal cord → hypothalamus

2. Suppression of TIDA neuron firing (reduces dopamine release)

3. Disinhibition of lactotrophs → acute PRL surge (5-10 fold above baseline within 30 min)

4. PRL stimulates milk production for next feeding cycle

This PRL surge also suppresses GnRH pulsatility → lactational amenorrhea: a natural though unreliable contraceptive effect of exclusive breastfeeding.

The Prolactin Receptor: Structure and Signaling

PRLR Structure

PRLR gene (chromosome 5p13-p12) encodes a Type 1 cytokine receptor with:

• •Extracellular domain: two fibronectin type III subdomains (D1, D2); each with ~200 aa; CRH motif (four conserved cysteines) and WSXWS motif (critical for ligand binding)
• •Single transmembrane helix (24 aa)
• •Intracellular domain: ~300 aa; associated with JAK2 kinase (not intrinsic kinase activity)

Multiple PRLR isoforms arise by alternative splicing of the intracellular domain:

• •Long form (PRLR-L): full-length; primary signaling isoform; activates all downstream pathways
• •Short forms (PRLR-S1, S2): truncated intracellular domains; may act as dominant negatives or attenuate signaling
• •Soluble form: shed extracellular domain (= prolactin-binding protein, PRLBP); serves as serum binding protein for prolactin

Signaling: 2:2 Complex → JAK2 → STAT5

Receptor activation:

1. Prolactin binds D1 domain of PRLR (binding site 1 on PRL)

2. This 1:1 complex recruits a second PRLR via binding site 2 on PRL

3. 2:2 complex forms (one PRL + two PRLR) → allosteric activation

4. JAK2 transphosphorylation: constitutively associated JAK2 kinases on adjacent PRLRs transphosphorylate each other and receptor tyrosines

5. STAT5A/B recruitment: phospho-tyrosines on PRLR recruit STAT5 via SH2 domain

6. JAK2 phosphorylates STAT5 → STAT5 dimerizes → nuclear translocation → DNA binding at gamma-interferon activation sites (GAS) → gene regulation

Key STAT5 target genes:

• •LALBA (α-lactalbumin): milk protein
• •CSN2 (β-casein): milk protein — classical prolactin target gene
• •WAP (whey acidic protein): milk protein
• •SOCS1/2/3 (suppressors of cytokine signaling): negative feedback
• •IGF-1: growth and lactation support
• •CYP11A1 and other steroidogenesis genes: in gonads

Additional signaling pathways:

• •Ras/MAPK/ERK1/2: proliferation, survival
• •PI3K/AKT: cell survival, protein synthesis
• •Src family kinases: Src, Fyn → actin remodeling, adhesion
• •PLC/PKC: calcium signaling

Physiological Roles of Prolactin

1. Mammary Gland Development and Lactation

Prolactin orchestrates the terminal differentiation of mammary epithelial cells during pregnancy and postpartum lactation:

• •Lobuloalveolar development: in pregnancy, estrogen + progesterone + PRL + EGF/IGF-1 drive branching morphogenesis and alveolar bud formation
• •Milk protein gene induction: postpartum, after progesterone withdrawal, PRL → STAT5 → expression of casein, α-lactalbumin, whey proteins
• •Milk synthesis and secretion: PRL regulates glucose uptake, fatty acid synthesis, and secretory IgA transport in mammary epithelium

Note: Milk let-down (ejection) is mediated by oxytocin, not prolactin. PRL drives production; oxytocin drives release.

2. Reproductive Axis Modulation

High prolactin suppresses GnRH pulsatility through:

• •Direct action on hypothalamic GnRH neurons (PRL-R expression on kisspeptin neurons, which drive GnRH)
• •TIDA neuron stimulation (PRL feeds back to increase dopamine release from TIDA, creating a unique "short-loop feedback" — the hormone its own inhibitor pathway)

This explains:

• •Lactational amenorrhea during breastfeeding
• •Hyperprolactinemia → amenorrhea, oligomenorrhea, infertility in women
• •Hyperprolactinemia → hypogonadism, erectile dysfunction, oligospermia in men

3. Immune Modulation

PRLR is expressed on T cells, B cells, NK cells, macrophages, and dendritic cells. Prolactin:

• •Promotes T cell proliferation and Th1 differentiation
• •Enhances B cell immunoglobulin production
• •Has been proposed as a survival signal for autoreactive lymphocytes — potentially explaining higher autoimmune disease rates in women (higher PRL levels) and PRL elevation in SLE/RA
• •Hyperprolactinemia in systemic lupus erythematosus correlates with disease activity in some studies; bromocriptine has shown benefit in some SLE trials

4. Metabolic Effects

• •Glucose metabolism: PRLR on pancreatic β-cells → insulin secretion enhancement; explains the increased β-cell mass and insulin secretion observed in pregnancy (adapting to the metabolic demands of fetal nutrition)
• •Fat metabolism: PRL promotes lipogenesis in mammary glands; in adipose tissue, PRL has complex effects (may promote central adiposity in hyperprolactinemia)
• •Appetite: PRL is orexigenic in some contexts, contributing to weight gain during lactation

5. Neurogenesis and CNS

• •PRL is produced locally in the brain (hypothalamus, choroid plexus)
• •Stimulates neurogenesis in the subventricular zone (SVZ) — demonstrated during pregnancy/lactation when hippocampal neurogenesis increases
• •May have anxiolytic effects during lactation (reducing maternal stress response)
• •PRLR null mice show reduced neurogenesis and increased anxiety-like behaviors

6. Extrapituitary Prolactin Production

"Extrapituitary" PRL is produced by:

• •T lymphocytes and B lymphocytes (autocrine/paracrine immune function)
• •Uterine decidua (during pregnancy; local uterine regulation)
• •Brain neurons
• •Skin
• •Prostate
• •Breast tissue

Extrapituitary PRL is regulated by promoter elements distinct from pituitary PRL and is not suppressed by dopamine, making it resistant to dopamine agonist therapy.

Hyperprolactinemia: Causes and Clinical Consequences

Causes

Physiological:

• •Pregnancy (PRL rises 10-20x, driven by estrogen)
• •Lactation/breastfeeding
• •Stress, exercise, sleep (acute elevations)
• •Sexual intercourse

Pathological — Pituitary:

• •Prolactinoma (lactotroph adenoma): most common pituitary tumor (~40% of pituitary adenomas); microprolactinoma (<10 mm) vs. macroprolactinoma (≥10 mm); may cause mass effects (headache, visual field defects from optic chiasm compression)
• •Other pituitary tumors causing "stalk effect" (GH-secreting, ACTH-secreting, non-functioning tumors)

Pathological — Pharmacological:

• •D2 antagonist antipsychotics: haloperidol, risperidone, amisulpride (strongly prolactin-elevating); clozapine, quetiapine (weakly or not prolactin-elevating due to loose D2 binding)
• •Antiemetics: metoclopramide, domperidone
• •Antihypertensives: methyldopa, verapamil
• •Opioids: through μ-opioid receptor suppression of TIDA neurons
• •SSRIs/SNRIs: modest PRL elevation via serotonin effect
• •Histamine H2 antagonists: cimetidine (older); ranitidine (less so)

Pathological — Other:

• •Hypothyroidism (elevated TRH)
• •Chronic kidney disease (reduced clearance)
• •Cirrhosis
• •Chest wall irritation (herpes zoster, surgical scars — afferent sensory arc mimicking suckling)
• •Macroprolactinemia (benign)

Clinical Consequences

Women:

• •Oligo/amenorrhea, anovulation, infertility
• •Galactorrhea (milk secretion outside lactation)
• •Decreased libido
• •Vaginal dryness (from low estrogen)
• •Osteoporosis (from prolonged hypogonadism)

Men:

• •Hypogonadotropic hypogonadism → testosterone deficiency
• •Erectile dysfunction
• •Oligospermia/azoospermia
• •Galactorrhea (uncommon)
• •Gynecomastia
• •Osteoporosis

Mass effects (macroprolactinoma):

• •Headache
• •Bitemporal hemianopia (optic chiasm compression)
• •Cranial nerve palsies
• •Hypopituitarism (compression of remaining pituitary)

Treatment of Hyperprolactinemia

Dopamine Agonists (First-Line for Prolactinomas)

Cabergoline (Dostinex): long-acting ergot-derived D2 agonist; administered 0.5-2 mg 1-2x weekly; normalizes PRL in ~80-90% of patients; reduces prolactinoma size by >50% in most macro-adenomas; superior to bromocriptine in efficacy and tolerability. Rare risk of cardiac valvulopathy at high doses (doses used for Parkinson's disease; standard hyperprolactinemia doses appear safe).

Bromocriptine (Parlodel): older ergot D2 agonist; effective but requires daily dosing and has more GI side effects; still used in pregnancy (more safety data than cabergoline).

Surgery: transsphenoidal surgery for macroprolactinomas refractory to medical therapy or with acute visual loss.

Radiotherapy: rarely used given the efficacy of dopamine agonists; for aggressive/malignant prolactinomas.

Drug-induced hyperprolactinemia: ideally switch to a PRL-sparing antipsychotic (clozapine, quetiapine, aripiprazole) if clinically feasible; alternatively add low-dose cabergoline.

Prolactin as a Research Tool and Biomarker

Measurement:

• •Serum PRL by immunoassay (ECLIA, CLIA, RIA)
• •Normal ranges: women ~3-30 ng/mL; men ~3-18 ng/mL; pregnancy up to 300 ng/mL
• •Macroprolactin assessment: PEG precipitation

Research applications:

• •STAT5 phosphorylation assay (pSTAT5 by WB or flow cytometry) — used as pharmacodynamic readout for PRLR signaling
• •Prolactin-responsive cell lines: Nb2 rat lymphoma (hyperexpresses PRLR; classic bioassay cell); MCF-7 breast cancer (endogenous PRLR)
• •Prl−/− mice: infertile females; reduced maternal behavior; immune dysfunction
• •PRLR−/− mice: inability to lactate; fertility defects; metabolic phenotype (increased weight, insulin resistance in some backgrounds)

Research Tools and Models

Current Research Frontiers

Prolactin in Breast Cancer

PRLR is overexpressed in ~25-50% of breast cancers. PRL activates STAT5, MAPK, and PI3K pathways promoting proliferation, survival, and drug resistance. The anti-PRLR antibody LFA102 (Novartis) was tested in breast cancer (Phase I/II) but showed limited single-agent efficacy. Combination with endocrine therapy and PRLR as a pharmacodynamic biomarker remain active areas.

Prolactin in Autoimmune Disease

PRL elevation in SLE correlates with disease activity (lupus nephritis, complement consumption). Whether anti-PRL or anti-PRLR approaches could provide disease modification in SLE remains an open question; small clinical trials of bromocriptine in SLE have shown some benefit.

Prolactin and Neuropsychiatric Effects

Antipsychotic-induced hyperprolactinemia causes sexual dysfunction in schizophrenia patients, contributing to medication non-adherence — a major clinical problem. Aripiprazole (D2 partial agonist) and low-dose cabergoline added to antipsychotics can normalize PRL without compromising antipsychotic effect. The neuropsychiatric consequences of PRL receptor activation in the CNS (anxiety, reward, maternal behavior) are under investigation.

16 kDa Anti-Angiogenic Prolactin Fragment

Cathepsin D cleavage of 23 kDa PRL produces 16 kDa N-terminal PRL — a fragment that INHIBITS endothelial cell proliferation and angiogenesis, opposite to full-length PRL. This fragment may be relevant in peripartum cardiomyopathy (a rare postpartum heart failure) — elevated cathepsin D activity in postpartum myocardium generates 16 kDa anti-angiogenic PRL, impairing cardiac vascularity. Bromocriptine has been tested as treatment in peripartum cardiomyopathy to suppress PRL production and thus reduce 16 kDa fragment generation.

Conclusion

Prolactin exemplifies the principle that a hormone's primary "name" role may be the least interesting of its biological functions. Named for its role in promoting milk production, prolactin has proven to be a broad-acting pleiotropic mediator with established functions in immunity, neurogenesis, β-cell proliferation, and metabolic adaptation to pregnancy — with emerging roles in cancer biology and autoimmune disease.

The pharmacology of prolactin regulation remains clinically essential: drug-induced hyperprolactinemia is one of the most common endocrine consequences of psychiatric medication, and the management of prolactinomas with dopamine agonists represents one of the earliest and most successful examples of medical therapy replacing surgical intervention for pituitary tumors.

For researchers, the PRLR/JAK2/STAT5 signaling axis serves as a model system for understanding cytokine receptor biology, and the extraordinary tissue distribution of PRLR ensures that prolactin biology will continue generating research questions across reproductive biology, immunology, oncology, and neuroscience.

Key Research Citations

1. Riddle OA, Bates RW, Dykshorn SW (1933). The preparation, identification and assay of prolactin — a hormone of the anterior pituitary. American Journal of Physiology, 105, 191-216.

3. Bole-Feysot C, et al. (1998). Prolactin and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocrine Reviews, 19(3), 225-268. PMID: 9626554

4. Freeman ME, et al. (2000). Prolactin: structure, function, and regulation of secretion. Physiological Reviews, 80(4), 1523-1631. PMID: 11015620

5. Melmed S, et al. (2011). Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 96(2), 273-288. PMID: 21296991

7. Goffin V, et al. (2002). Prolactin: the new biology of an old hormone. Annual Review of Physiology, 64, 47-67. PMID: 11826265

8. Gonzalez-Parra E, et al. (2010). Prolactin and kidney disease. Journal of the American Society of Nephrology, 21(11), 1810-1812.

9. Capuron L, et al. (2011). Prolactin and mental illness: a comprehensive review. Frontiers in Endocrinology, 2, 1-11.

10. Sinha YN (1995). Structural variants of prolactin: occurrence and physiological significance. Endocrine Reviews, 16(3), 354-369. PMID: 7671851

---

This article is intended for Research Use Only (RUO). Prolactin-related research tools and compounds described herein are not approved for human therapeutic use outside of specifically indicated clinical applications. All research involving prolactin receptor signaling must comply with applicable institutional and regulatory guidelines. This content does not constitute medical advice.